Correction: The Role of Interleukin−6 in Prematurity Complications: Transitioning from Biomarker to Therapeutic Target
-
By
-
Shuzhe Xiao
-
Qi Zheng
-
Lingling Wang
-
Zhiqiu Wang
-
Guangliang Bi
-
Jie Yang
-
September 10, 2026
Objective:
To correct errors in the previously published article regarding the role of Interleukin−6 (IL−6) in complications associated with prematurity.
Approach:
- Correction of Table 1: Corrected errors in Table 1 regarding AUC, missing entries, and spelling mistakes.
- Text Corrections: Corrected grammatical errors and redundant sentences in the text.
Key Findings:
- IL−6 is associated with various complications in preterm infants, including BPD, NES, ROP, AKI, NEC, and HIE.
- IL−6 serves as a potential predictor for complications arising from prematurity.
- Research indicates IL−6 is a significant biomarker for early diagnosis of neonatal septicemia.
Interpretation:
The corrections clarify the role of IL−6 in prematurity complications and improve the accuracy of the data presented.
Limitations:
- The applicability of findings from HIE studies, which primarily involved term infants, to preterm infants remains uncertain.
- The IL−6 threshold for diagnosing neonatal septicemia is still not established.
Conclusion:
The article has been updated to reflect necessary corrections and enhance the clarity of IL−6's role in prematurity complications.
Sources:
